Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in the development of innovative biologic therapeutic candidates. The company utilizes proprietary modular protein engineering platforms to create therapies with enhanced attributes and mechanisms, targeting challenging and validated disease areas. INBX's primary focus is on advancing its oncology pipeline, with a goal of addressing unmet medical needs and transitioning into a commercial-stage biopharmaceutical company.
-
INBRX-109 - A tetravalent death receptor 5 (DR5) agonist under investigation for treating various cancers, including colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, chondrosarcoma, synovial sarcoma, Ewing sarcoma, and pancreatic adenocarcinoma. It has received orphan drug designation for unresectable or metastatic conventional chondrosarcoma.
-
INBRX-106 - A hexavalent OX40 agonist being studied in patients with non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
-
License Fee Revenue - Generates income through licensing agreements for its proprietary technologies and therapeutic candidates.
-
Grant Revenue - Previously recognized revenue from grants, such as a completed grant with the Department of Defense, though no grant revenue was recorded in the most recent period.
You might also like
Research analysts covering Inhibrx Biosciences.
Recent press releases and 8-K filings for INBX.
Inhibrx Reports Positive OzekiVART Trial Results and Market Opportunities
·$INBXNew Projects/Investments
M&A
Product Launch
- Inhibrx announced positive top-line results from its registrational trial of OzekiVART in unresectable or metastatic chondrosarcoma, demonstrating a median Progression-Free Survival (PFS) of 5.52 months compared to 2.66 months for placebo, with a hazard ratio of 0.479 (p-value <0.0001).
- The company plans to file a Biologics License Application (BLA) for OzekiVART in chondrosarcoma in the second quarter of 2026.
- Interim results for OzekiVART in combination therapies showed a 23% overall confirmed response rate and 92% disease control rate in evaluable colorectal cancer patients, and a 64% overall response rate and 92% disease control rate in evaluable Ewing sarcoma patients.
- The estimated combined market potential for chondrosarcoma, late-line colorectal cancer, and Ewing sarcoma is greater than $2.5 billion, with individual global peak revenue estimates exceeding $500 million for chondrosarcoma and Ewing sarcoma, and over $1.5 billion for late-line colorectal cancer in the U.S..
- Inhibrx intends to transact the OzekiVART program with a third party to maximize shareholder value and is actively engaged in discussions.
7 days ago
Inhibrx Reports Positive Top-Line Results for Ozekibart in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma
·$INBXProduct Launch
New Projects/Investments
- Inhibrx reported positive top-line results from its registrational ChonDRAgon trial for ozekibart in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479 (p-value < 0.0001). The company plans to file a Biologics License Application (BLA) in Q2 2026.
- In expansion cohorts, ozekibart in combination with FOLFIRI achieved a 23% overall confirmed response rate and a 92% disease control rate in heavily pretreated colorectal cancer patients.
- For relapsed or refractory Ewing sarcoma, ozekibart combined with irinotecan and temozolomide showed a 64% overall response rate and a 92% disease control rate in evaluable patients.
- The estimated global peak revenue for ozekibart could exceed $500 million each for chondrosarcoma and Ewing sarcoma, and potentially exceed $1.5 billion in late-line colorectal cancer in the U.S. alone, leading to a combined market potential of greater than $2.5 billion across these indications.
- Inhibrx intends to transact on the ozekibart program with a third party to maximize shareholder value.
7 days ago
Inhibrx Announces Positive OzekiVART Registrational Trial Results and Strategic Plans
·$INBXProduct Launch
New Projects/Investments
M&A
- Inhibrx reported positive top-line results from its registrational trial (Chondragon) of OzekiVART in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, representing a 52% reduction in the risk of progression or death (p-value < 0.0001). The company plans to file a Biologics License Application (BLA) in Q2 2026.
- In expansion cohorts, OzekiVART showed a 23% overall confirmed response rate and 92% disease control rate in heavily pretreated colorectal cancer (CRC) patients when combined with FOLFIRI. For relapsed or refractory Ewing sarcoma, in combination with irinotecan and temozolomide, it achieved a 64% overall response rate and 92% disease control rate.
- The estimated global peak revenue for OzekiVART could exceed $500 million for chondrosarcoma and $500 million for Ewing sarcoma, while the late-line U.S. market opportunity for CRC could exceed $1.5 billion, totaling a combined market potential of greater than $2.5 billion across these indications.
- Inhibrx aims to maximize shareholder value by transacting on the OzekiVART program with a third party, focusing on tax efficiency and dilution sensitivity, and is actively engaged in discussions.
7 days ago
Inhibrix Reports Positive Registrational Trial Results for Ozekibart in Chondrosarcoma and Provides Updates on Other Indications
·$INBXProduct Launch
New Projects/Investments
M&A
- Inhibrix reported positive top-line results from its registrational trial of ozekibart in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, and a 52% reduction in the risk of progression or death (P < 0.0001).
- Based on these compelling results, Inhibrix plans to file a Biologics License Application (BLA) in 2026.
- Encouraging updates were also provided for expansion cohorts of ozekibart in colorectal cancer (23% overall confirmed response rate, 92% disease control rate) and Ewing sarcoma (64% overall response rate, 92% disease control rate).
- Inhibrix estimates the combined market potential for chondrosarcoma, late-line colorectal cancer, and Ewing sarcoma to be greater than $2.5 billion, with global peak revenue for chondrosarcoma and Ewing sarcoma each potentially exceeding $500 million, and the U.S. late-line colorectal cancer market exceeding $1.5 billion.
- The company's goal is to transact on the ozekibart program by partnering with a third party to bring value to shareholders.
7 days ago
Inhibrx Biosciences to Present Topline Results for Ozekibart in Chondrosarcoma
·$INBXNew Projects/Investments
- Inhibrx Biosciences will host a webcast presentation on October 23, 2025, at 1:30 p.m. PT, to provide topline results from its registrational ChonDRAgon study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma.
- The company will also provide updates on ongoing expansion trials investigating ozekibart in late-line colorectal cancer and refractory Ewing sarcoma.
- Ozekibart (INBRX-109) has received FDA Fast Track designation (January 2021) and Orphan Drug designation (November 2021) for chondrosarcoma.
Oct 22, 2025, 8:01 PM
Inhibrx Biosciences Reports Q2 2025 Financial Results and Upcoming Clinical Milestones
·$INBXEarnings
New Projects/Investments
M&A
- Inhibrx Biosciences reported a net loss of $28.7 million, or $1.85 per share, for the second quarter of 2025, a significant decline from a net income of $1.9 billion in the second quarter of 2024, primarily due to a $2.0 billion gain from the INBRX-101 transaction recorded in the prior year.
- As of June 30, 2025, the company held $186.6 million in cash and cash equivalents.
- Research and development expenses decreased substantially to $22.3 million in Q2 2025 from $67.6 million in Q2 2024, and general and administrative expenses fell to $6.4 million from $93.4 million, largely due to non-recurring expenses and activities related to the INBRX-101 program and transaction in 2024.
- The company anticipates key clinical trial data readouts, with results from the ozekibart (INBRX-109) Phase 2 trial expected by late October 2025 and initial Phase 2 data for INBRX-106 during the fourth quarter of 2025.
Aug 13, 2025, 8:05 PM
Inhibrx Biosciences Announces Leadership Changes & Updates
·$INBXManagement Change
M&A
Executive Compensation
- David J. Matly is promoted to President effective April 1, 2025, with an increased base salary of $601,670, 50,000 stock options vesting over four years, and notable contributions to the $2.2B asset sale of INBRX-101 to Sanofi .
- Dr. Brendan Eckelman, co-founder and former CSO, departs to launch a new biotech company, with his resignation triggering accelerated vesting of 50,000 stock options and an extended exercise period through October 1, 2026 .
- Dr. Carlos Bais is appointed as Chief Scientific Officer .
Apr 1, 2025, 8:05 PM
Inhibrx Biosciences Reports Q4 and Fiscal Year 2024 Results
·$INBXDebt Issuance
M&A
- Inhibrx Biosciences reported its Q4 and fiscal year 2024 financial results following the divestiture of the INBRX-101 program and a subsequent spin-off, while advancing two clinical programs with anticipated data readouts within the next 12 months.
- The company bolstered liquidity by reporting $152.6 million in cash as of December 31, 2024, and receiving $100 million from a loan agreement with Oxford Finance—raising cash to $230.5 million by February 2025.
- Q4 performance improved with a reduced net loss of $47.9 million (from $93.6 million in Q4 2023) and a turnaround to a fiscal year net income of $1.7 billion, reflecting the impact of the spin-off transaction.
Mar 17, 2025, 8:05 PM
Inhibrx Biosciences Reports Q4 2024 Financial Results
·$INBXEarnings
Debt Issuance
New Projects/Investments
- The company reported a Q4 net loss of $47.9 million while achieving full-year net income of $1.7 billion, reflecting the impact of its recent spin-off and related transactions.
- On January 13, 2025, Inhibrx secured $100.0 million in gross proceeds under a loan agreement with Oxford Finance LLC, with an option for an additional $50.0 million, highlighting its enhanced liquidity and funding strategy.
- The company updated its clinical pipeline with two ongoing trials, including data readouts for ozekibart expected within the next 12 months, underscoring a continued focus on advancing its therapeutic candidates.
Mar 17, 2025, 12:00 AM